Core Viewpoint - Rosen Law Firm is reminding investors who purchased Reddit, Inc. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from October 29, 2024, to May 20, 2025, and the lead plaintiff deadline is August 18, 2025 [1]. - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3]. Group 3: Case Allegations - The lawsuit alleges that during the class period, defendants made false statements and failed to disclose significant changes in Google Search's algorithm that negatively impacted Reddit's traffic [4]. - It is claimed that these algorithm changes led to a zero-click search reality, where users found answers directly on Google without visiting Reddit, thus reducing traffic [4]. - The lawsuit asserts that defendants lacked a reasonable basis for their outlook on user rates and advertising revenues due to these undisclosed issues [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DoubleVerify Holdings, Inc. common stock during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought DoubleVerify common stock between November 10, 2023, and February 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 21, 2025 [3]. Group 2: Case Allegations - The lawsuit alleges that DoubleVerify made false and misleading statements regarding its business operations, including the shift of customers' ad spending to closed platforms where DoubleVerify's capabilities were limited [5]. - It is claimed that the development of technology for closed platforms was more expensive and time-consuming than disclosed, impacting the monetization of DoubleVerify's high-margin advertising optimization services [5]. - The lawsuit also states that DoubleVerify's competitors were better positioned to incorporate AI into their offerings, adversely affecting DoubleVerify's competitive edge and profits [5]. - Additional allegations include systematic overbilling of customers for ad impressions served to declared bots and misleading risk disclosures that characterized adverse facts as mere possibilities [5].

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for alleged misleading statements regarding its drug candidates, potentially impacting investors who purchased securities during the specified period [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to purchasers of Biohaven securities between March 24, 2023, and May 14, 2025 [1]. - Allegations include overstated regulatory prospects for the drug troriluzole and its efficacy for treating spinocerebellar ataxia and bipolar disorder, which may have negatively affected Biohaven's business and financial condition [5]. Group 2: Investor Information - Investors who purchased Biohaven securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in previous years, including over $438 million in 2019 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of 3D Systems Corporation during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the 3D Systems Corporation securities is from August 13, 2024, to May 12, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 12, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, 3D Systems made false and misleading statements regarding its business resilience and the impact of weakened customer spending [4]. - It is claimed that the updated milestone criteria in a partnership with United Therapeutics Corporation would negatively affect 3D Systems' Regenerative Medicine Program revenue [4]. - The lawsuit asserts that these misleading public statements resulted in investor damages when the true details became known [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DoubleVerify Holdings, Inc. common stock during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought DoubleVerify common stock between November 10, 2023, and February 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by July 21, 2025 [3]. Group 2: Case Allegations - The lawsuit alleges that DoubleVerify made false and misleading statements regarding its business operations, including the shift of ad spending from open exchanges to closed platforms, which limited its technological capabilities [5]. - It is claimed that DoubleVerify's ability to monetize its high-margin advertising optimization services was significantly hampered due to the high costs and time required for technology development for closed platforms [5]. - The lawsuit also states that DoubleVerify's competitors were better positioned to integrate AI into their offerings, negatively impacting DoubleVerify's competitive edge and profitability [5]. - Additional allegations include systematic overbilling of customers for ad impressions served to declared bots and misleading risk disclosures that characterized adverse facts as mere possibilities [5].

Core Points - Rosen Law Firm is reminding purchasers of Hims & Hers Health, Inc. common stock of the lead plaintiff deadline for a class action lawsuit, which is August 25, 2025 [1] - Investors who purchased Hims common stock during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] Company Details - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy for Hims subscribers [4] - Specific claims include that Hims failed to disclose the nature of its collaboration with Novo, which would ensure continued access to Wegovy, and that positive statements were made about the partnership while omitting critical details [4] Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [3] - Rosen Law Firm has a history of successful settlements in securities class actions, including a record settlement against a Chinese company and significant recoveries for investors [3]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of SelectQuote, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Allegations and Impact - SelectQuote has been charged by the U.S. Department of Justice for allegedly paying illegal kickbacks to brokers from 2016 to 2021, which resulted in a significant stock price drop of 19.2% on May 1, 2025 [3]. - The investigation by Rosen Law Firm is a response to these allegations, indicating potential legal repercussions for SelectQuote and its shareholders [1][2]. Group 2: Class Action Information - Shareholders who purchased SelectQuote securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. - Interested investors can join the class action by submitting a form or contacting the law firm directly for more information [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements including over $438 million secured in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Red Cat Holdings, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on July 22, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Red Cat securities between March 18, 2022, and January 15, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 22, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that Red Cat Holdings made false and misleading statements regarding the production capacity of its Salt Lake City Facility and the value of the SRR Program's Tranche 2 contract, leading to investor damages when the truth was revealed [4].

Group 1 - A class action lawsuit has been filed on behalf of purchasers of Petco Health and Wellness Company, Inc. securities between January 14, 2021 and June 5, 2025 [1][5] - Investors who purchased Petco securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][5] - The lawsuit alleges that Petco made false and misleading statements regarding its business model and the sustainability of its pandemic-related growth [5] Group 2 - The Rosen Law Firm, which is representing the investors, has a strong track record in securities class actions, having secured over $438 million for investors in 2019 alone [4] - The firm has been recognized for its success in securities class action settlements, being ranked No. 1 by ISS Securities Class Action Services in 2017 [4] - Investors interested in joining the class action can find more information through the Rosen Law Firm's website or by contacting their representatives [3][6]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025, and the lead plaintiff deadline is August 25, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][5] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - In 2019, Rosen Law Firm secured over $438 million for investors, showcasing its effectiveness in representing clients [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy [4] - Specific claims include that Hims misrepresented the nature of its collaboration with Novo and the offerings of compounded semaglutide products [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages due to the misleading information [4]